Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Recalled "super greens" supplement linked to dozens of salmonella cases, CDC says - 2Teen drug use remains low, but survey finds small rise in heroin and cocaine use
- 3Nitty gritty Manual for Picking Agreeable Tennis shoes
- 4A Gastronomic Experience in Healthy Enjoyments: A Survey of \Nutritious and Tasty\ Solid Cooking Recipe Book
- 5As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- Vote in favor of your Number one kind of juice
- The Manual for Electric Vehicles that will be hot merchants in 2023
- Building an Individual Brand: Illustrations from Forces to be reckoned with
- Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects
- Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
- Melodic Combination d: A Survey of \Unrecorded Music Energy\ Show
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- What to know about cheese voluntarily recalled in 20 states
